ADCT Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
ADC Therapeutics SA (ADCT) is not a strong buy for a beginner investor with a long-term strategy at this time. The stock shows mixed technical indicators, weak financial performance, and lacks significant positive catalysts to justify immediate investment. While there is potential for long-term growth with ZYNLONTA, the current financials and market sentiment do not support a strong buy recommendation.
The MACD histogram is slightly positive at 0.017, indicating weak bullish momentum. RSI is neutral at 47.28, and moving averages are bullish (SMA_5 > SMA_20 > SMA_200). However, the stock is trading near its support level (S1: 3.917), and recent price action shows a downward trend with a -3.28% regular market change and -2.81% pre-market change.
ADC Therapeutics amended its royalty purchase agreement, reducing the change of control payment, which enhances strategic flexibility. Additionally, ZYNLONTA is projected to achieve peak annual revenues of $600 million to $1 billion in the U.S. starting in 2027, supported by HealthCare Royalty's confidence in its clinical data.
The company's financial performance in Q3 2025 showed declines across revenue (-11.03% YoY), net income (-6.83% YoY), EPS (-14.29% YoY), and gross margin (-2.84% YoY). Additionally, the stock has a 70% chance of declining by -9.12% over the next month based on historical patterns.
In Q3 2025, ADC Therapeutics reported a revenue drop of -11.03% YoY to $16.43 million, a net income loss of -$40.97 million (-6.83% YoY), and a decline in EPS to -0.36 (-14.29% YoY). Gross margin also decreased slightly to 92.68% (-2.84% YoY).
No recent analyst rating or price target changes were provided for ADCT.
